9th Jun 2016 08:48
LONDON (Alliance News) - Contract research organisation Cyprotex PLC on Thursday said it has bought an IntelliCyt iQue screener in order to expand its cell-based services.
The screener uses flow cytometry to analyse fluorescently labelled particles or cells in a fluid as they flow past a detector, Cyprotex said.
"Expanding into the field of biologics is a critical step in the continued growth of Cyprotex. Flow cytometry not only allows us to address this market but enables us to target immune-based phenotypic screening and safety assessment of small molecules," said Anthony Baxter, Cyprotex's chief executive.
Shares in Cyprotex were untraded on Thursday, having last traded at 107.61 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L